PRIME-ROSE

Combining expertise across borders to promote Precision Cancer Medicine in Europe. PRIME-ROSE - Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials - is a European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. PRIME-ROSE will run for five years (2023 – 2028), and the consortium consists of altogether 24 partners, including nine beneficiaries and fifteen associated partners. In addition, PRIME-ROSE is part of the Cancer Mission cluster of projects on Diagnosis and Treatment. The pan-European PRIME-ROSE project is led by Professor Kjetil Taskén, Head of Institute for Cancer Research at Oslo University Hospital Comprehensive Cancer Centre in Norway. The PRIME-ROSE vision is access to affordable Precision Cancer Medicine (PCM) that prolongs life at the best quality possible for all cancer patients. The project contains eight work packages (WPs): WP1 is about data aggregation whereas WP2 is focusing on randomized, synthetic control cohorts. In WP3 the focus is to initiate and run expansion cohorts whereas WP4 is about harmonisation of off-label use and repurposing medicines. WP5 is about EU implementation in everyday practice and in WP6 the focus is social innovation for access to precision cancer medicine. WP 7 is management and coordination of the project and finally, WP 8 is about dissemination.